Cellectis (CLLS) Tops Q2 EPS by 1c

Cellectis (NASDAQ: CLLS) reported Q2 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $3.47 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.

You May Also Be Interested In

• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• AbbVie (ABBV) call put ratio 2.2 calls to 1 put into near deal to acquire Apogee Therapeutics (APGE), FT reports
• Cantor Fitzgerald Starts Adlai Nortye Ltd. (ANL) at Overweight